Targeted therapy in the treatment of cancer has significantly improved the clinical benefits over conventional therapy in indications like head and neck, colorectal etc. Molecular targets such as epidermal growth factor (EGFR) have been well established in the treatment of various solid tumors. Screening for the molecular target and treating the patient with the respective targeted therapeutic agents with or without combination therapy had changed the treatment modalities in recent past. Nimotuzumab is a humanized monoclonal antibody binds to the extracellular domain of EGFR, and consequently inhibits tyrosine kinase activation. Nimotuzumab is the only-affinity optimized anti-EGFR monoclonal antibody exhibits superior safety profile among the class of anti-EGFR agents. Anti-tumor efficacy of nimotuzumab was well correlated with the level EGFR expression in tumors in vitro/ in vivo